Abstract
In this research, the in silico interaction between curcumin and cyclooxygenase 2 (COX-2) was investigated using molecular docking with the AutoDock 4.0 software application. This study aimed to determine the pharmacokinetic profile of the compound, affinity, and exchange of curcumin with COX-2 inhibitors in silico. Curcumin’s interactions with COX-2 were compared to those of the known COXinhibitor, celecoxib. The pharmacodynamic test was used to show the free bond energy. Curcumin demonstrated anticancer activity by inhibiting the metabolism of arachidonic acid through the enzyme COX-2 and inhibiting free radicals in the enzymatic pathway. This was indicated by the value free energy (ΔG) of the curcumin compounds having a binding energy value of -8.81 kcal/mol, which is smaller than that of arachidonic acid (-5.20 kcal/mol). However, celecoxib had a more stable bond with the COX-2 inhibitors than curcumin, with a value of -10.11 kcal/mol. As a result, curcumin can be considered a suitable lead compound in developing new COX-2 inhibitors, which are a potential target for anticancer drugs.
 Keywords: curcumin, COX-2 inhibitor, anticancer
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
